戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 us encouraging clinicians to keep TAC at the usual dose.
2 glutinin for each antigen (40 percent of the usual dose), and 119 to receive an intramuscular injecti
3 from folic acid supplementation taken at the usual doses are no greater than small.
4 45 in the high-dose protein group and 656 in usual dose group).
5 as 10.0+/-3.7, and that for the moderate and usual-dose groups were 6.7+/-2.9 and 6.6+/-3.6, mumol/kg
6                               In patients on usual dose lipid-lowering medication (n = 1,910) there w
7 ically manifest vascular disease using no or usual dose lipid-lowering medication, low plasma HDL-C l
8 ing that platelet doses of half to twice the usual dose of 2.2 x 10(11) platelets/transfusion/body su
9 et doses in ranges between half to twice the usual dose of 2.2 x 10(11) platelets/transfusion/BSA hav
10 s in TIMI 3 flow when combined with half the usual dose of alteplase.
11 s, patients were randomly administered their usual dose of CsA with either 8 ounces of grapefruit jui
12               Patients received either their usual dose of levothyroxine (n = 23) or combination ther
13 four adults were vaccinated with 1/50 of the usual dose of meningococcal polysaccharide vaccine (1 mi
14 rdiovascular instability unresponsive to the usual doses of inotropes or vasopressors.
15 L-C on vascular events in patients using no, usual dose, or intensive lipid-lowering therapy.
16  for baseline WBPB, high dose (P = 0.036 vs. usual dose, P = 0.047 vs. moderate dose), but not modera
17  high-dose protein (>=2.2 g/kg per day) with usual dose protein (<=1.2 g/kg per day) started within 9
18 ose compared with 50.2% (46.0%-54.3%) in the usual dose protein group (hazard ratio 0.91, 95% CI 0.77
19 roup compared with 32.1% (208 of 648) in the usual dose protein group (relative risk 1.08, 95% CI 0.9
20 omly allocated (1:1) to high-dose protein or usual dose protein, stratified by site.
21 ndomized into a high-dose (>= 2.2 g/kg/d) or usual-dose protein group (<= 1.2 g/kg/d).
22  dose), but not moderate dose (P = 0.893 vs. usual dose) protein led to larger increases in WBPB.
23 emental treatment effect of high-dose versus usual-dose statin therapy in individual coronary artery
24 ts for whom the benefits of high-dose versus usual-dose statin therapy outweigh potential harm.